Clinical trial
A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's…
NCT00284804 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00284804 |
|---|---|
| Title | A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease |
| Official title | An Open-label, Randomized, Multicenter, Phase II Study of MDX-060 in Combination With Gemcitabine, MDX060 in Combination With Dexamethasone, and Gemcitabine Monotherapy in Patients With Relapsed or Refractory Hodgkin's Disease |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hodgkin's Disease |
| Intervention type | Drug |
| Interventions | MDX-060 |
| Enrollment | 74 |
| Start date | Nov 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | Oct 1, 2009 |
| First posted | Feb 1, 2006 |
| Last update posted | Oct 12, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: